Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure

[1]  R. Gur,et al.  Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. , 1998, The American journal of psychiatry.

[2]  J. Price,et al.  Glial reduction in the subgenual prefrontal cortex in mood disorders. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Arita,et al.  D2 Dopamine-Receptor-Mediated Inhibition of Proliferation of Rat Lactotropes in Culture Is Accompanied by Changes in Cell Shape , 1998, Neuroendocrinology.

[4]  P. Goldman-Rakic,et al.  Dopaminergic regulation of cerebral cortical microcirculation , 1998, Nature Neuroscience.

[5]  J. Sweeney,et al.  Decreased caudate volume in neuroleptic-naive psychotic patients. , 1998, The American journal of psychiatry.

[6]  John A. Sweeney,et al.  Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? , 1998, Journal of psychiatric research.

[7]  K. Seksel,et al.  Use of clomipramine in the treatment of anxiety-related and obsessive-compulsive disorders in cats. , 1998, Australian veterinary journal.

[8]  J. Price,et al.  Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders , 1998, Molecular Psychiatry.

[9]  P. Goldman-Rakic,et al.  The cerebral cortex: a case for a common site of action of antipsychotics. , 1998, Trends in pharmacological sciences.

[10]  G. Walbroehl,et al.  Recognition and treatment of obsessive-compulsive disorder. , 1998, American family physician.

[11]  P. Goldman-Rakic,et al.  Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three‐dimensional, stereologic counting method , 1998, The Journal of comparative neurology.

[12]  P. Goldman-Rakic,et al.  Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. , 1998, Archives of general psychiatry.

[13]  P S Goldman-Rakic,et al.  5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. JakabR,et al.  霊長類大脳皮質の5‐ヒドロキシトリプタミン2Aセロトニン受容体 錐体細胞先端樹状突起での幻覚剤及び抗精神病剤の作用部位 , 1998 .

[15]  C. Tamminga,et al.  Schizophrenia and glutamatergic transmission. , 1998, Critical reviews in neurobiology.

[16]  759 Chronic neuroleptic drug treatment induces mild gliosis in the prefrontal cortex of rhesus monkeys , 1997, Schizophrenia Research.

[17]  P. Goldman-Rakic,et al.  107 Marked glial neuropathology in prefrontal cortex distinguishes bipolar disorder from schizophrenia , 1997, Schizophrenia Research.

[18]  S. Hirsch,et al.  106 A neuroanatomical study of glial cells in schizophrenia , 1997, Schizophrenia Research.

[19]  P. Magistretti,et al.  The Cellular Bases of Functional Brain Imaging: Evidence for Astrocyte-Neuron Metabolic Coupling , 1997 .

[20]  J. Yoshikawa,et al.  Dopamine as a novel antimigration and antiproliferative factor of vascular smooth muscle cells through dopamine D1-like receptors. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[21]  P. Goldman-Rakic,et al.  Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[22]  F. Pfrieger,et al.  Synaptic efficacy enhanced by glial cells in vitro. , 1997, Science.

[23]  C. Tamminga,et al.  The Effect of Chronic Haloperidol Treatment on Dendritic Spines in the Rat Striatum , 1997, Experimental Neurology.

[24]  L. Zuck,et al.  Antipsychotic drug effects on glutamatergic activity , 1997, Brain Research.

[25]  A. Cincotta,et al.  Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation. , 1997, Atherosclerosis.

[26]  A. Saiardi,et al.  Antiproliferative Role of Dopamine: Loss of D2 Receptors Causes Hormonal Dysfunction and Pituitary Hyperplasia , 1997, Neuron.

[27]  S. Marder,et al.  Does risperidone improve verbal working memory in treatment-resistant schizophrenia? , 1997, The American journal of psychiatry.

[28]  P. Goldman-Rakic,et al.  Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  B. Jones,et al.  A case report of risperidone-induced obsessive-compulsive symptoms. , 1997, Journal of clinical psychopharmacology.

[30]  J. Kulisevsky,et al.  Obsessive-compulsive disorder associated with brain lesions , 1996, Neurology.

[31]  W. Honer,et al.  Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone , 1996, Biological Psychiatry.

[32]  Kenji Nakamura,et al.  Dopamine 02 receptor plays a critical role in cell proliferation and proopiomelanocortin expression in the pituitary , 1996, Genes to cells : devoted to molecular & cellular mechanisms.

[33]  J. Trojanowski,et al.  Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia , 1996, Acta Neuropathologica.

[34]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[35]  P. Goldman-Rakic,et al.  Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  M. Jenike,et al.  Frontal abnormalities in a patient with obsessive-compulsive disorder , 1995, Neurology.

[37]  P. Goldman-Rakic,et al.  Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. , 1995, Archives of general psychiatry.

[38]  M. Keshavan,et al.  Changes in caudate volume with neuroleptic treatment , 1994, The Lancet.

[39]  H. Meltzer,et al.  Recent advances in the pharmacotherapy of schxzophrenia , 1994, Acta psychiatrica Scandinavica. Supplementum.

[40]  W. Honer,et al.  Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. , 1994, The American journal of psychiatry.

[41]  P. Magistretti,et al.  Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Remington,et al.  Risperidone and obsessive-compulsive symptoms. , 1994, Journal of clinical psychopharmacology.

[43]  J. Lieberman,et al.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.

[44]  A. Levey,et al.  Localization of neuronal and glial glutamate transporters , 1994, Neuron.

[45]  A. Janowsky,et al.  Haloperidol-induced morphological changes in striatum are associated with glutamate synapses , 1994, Brain Research.

[46]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[47]  P. Goldman-Rakic,et al.  A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[48]  E. Lindström,et al.  Changes in Single Symptoms and Separate Factors of the Schizophrenic Syndrome after Treatment with Risperidone or Haloperidol , 1994, Pharmacopsychiatry.

[49]  F. Benes,et al.  The effects of chronic haloperidol administration on GABA‐immunoreactive. Axon terminals in rat medial prefrontal cortex , 1994, Synapse.

[50]  D. Sibley,et al.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[51]  N. Yamaguchi,et al.  In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol , 1994, Pharmacology Biochemistry and Behavior.

[52]  D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations. , 1993, The Journal of pharmacology and experimental therapeutics.

[53]  Y. Khan,et al.  Cellular distribution of dopamine D1 and D2 receptors in rat medial prefrontal cortex , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[54]  I. Kusumi,et al.  Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. , 1993, The Journal of pharmacology and experimental therapeutics.

[55]  A Labelle,et al.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.

[56]  J. Kerns,et al.  Synaptic plasticity in the rat striatum following chronic haloperidol treatment. , 1992, Clinical neuropharmacology.

[57]  J. Lieberman,et al.  Duration of psychosis and outcome in first-episode schizophrenia. , 1992, The American journal of psychiatry.

[58]  V. Pickel,et al.  Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: Implications for the pathogenesis of neuroleptic-induced movement disorders , 1992, Experimental Neurology.

[59]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[60]  P. Goldman-Rakic,et al.  The anatomy of dopamine in monkey and human prefrontal cortex. , 1992, Journal of neural transmission. Supplementum.

[61]  F. Benes,et al.  Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. , 1991, Archives of general psychiatry.

[62]  F. Benes,et al.  Evidence for ultrastructural changes in cortical axodendritic synapses following long-term treatment with haloperidol or clozapine. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[63]  P. Eriksson,et al.  Mu and delta opiate receptors in neuronal and astroglial primary cultures from various regions of the brain—coupling with adenylate cyclase, localisation on the same neurones and association with dopamine (D1) receptor adenylate cyclase , 1991, Neuropharmacology.

[64]  B. Bunney,et al.  Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia , 1991, Schizophrenia Research.

[65]  R. Fahlbusch,et al.  Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors. , 1990, The Journal of clinical endocrinology and metabolism.

[66]  P. Goldman-Rakic,et al.  Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  T. Crow,et al.  Schizophrenia and the brain: a prospective clinico-neuropathological study , 1990, Psychological Medicine.

[68]  P. Seeman.  Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage , 1990, Acta psychiatrica Scandinavica. Supplementum.

[69]  F. Buonanno,et al.  Focal striatal abnormalities in a patient with obsessive-compulsive disorder. , 1989 .

[70]  S. Deutsch,et al.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. , 1989, Clinical neuropharmacology.

[71]  P. Rakic,et al.  Three‐dimensional counting: An accurate and direct method to estimate numbers of cells in sectioned material , 1988, The Journal of comparative neurology.

[72]  P. Goldman-Rakic,et al.  Common cortical and subcortical targets of the dorsolateral prefrontal and posterior parietal cortices in the rhesus monkey: evidence for a distributed neural network subserving spatially guided behavior , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[73]  George W.Arana,et al.  Handbook of psychiatric drug therapy , 1987 .

[74]  F. Benes,et al.  Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats , 1985, Brain Research.

[75]  Francine M. Benes,et al.  The effects of haloperidol on synaptic patterns in the rat striatum , 1985, Brain Research.

[76]  H. Kornhuber,et al.  Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats. , 1983, European neurology.

[77]  J. Stevens,et al.  Neuropathology of schizophrenia. , 1982, Archives of general psychiatry.

[78]  T. J. Forrest,et al.  Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. , 1981, Journal of pharmacological methods.

[79]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[80]  F. Henn,et al.  Possible relationship between glial cells, dopamine and the effects of antipsychotic drugs , 1977, Nature.

[81]  W. Nauta,et al.  Columnar distribution of cortico-cortical fibers in the frontal association, limbic, and motor cortex of the developing rhesus monkey , 1977, Brain Research.

[82]  W. Nauta,et al.  An intricately patterned prefronto‐caudate projection in the rhesus monkey , 1977, The Journal of comparative neurology.

[83]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[84]  A. Walker,et al.  A cytoarchitectural study of the prefrontal area of the macaque monkey , 1940 .